Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]
News [2550]
Articles [106]
Editorials [3]
Conferences [84]
elearning [20]
Atezolizumab v docetaxel for NSCLC: results from the OAK trial
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Significant survival gains with atezolizumab for NSCLC
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Pembrolizumab new option for firstline treatment of advanced lung cancer with...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Pembrolizumab plus chemo as firstline therapy for NSCLC
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Firstline pembrolizumab plus chemo improves NSCLC outcomes
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
Immunotherapy and treatment advances in small cell lung cancer
Prof Dean Fennell - University of Leicester, Leicester, UK
Immunotherapy and treatment advances in small cell lung cancer ( Prof Dean Fennell - University of Leicester, Leicester, UK )
6 Oct 2016
Lung cancer screening in the UK
Prof John Field - University of Liverpool, Liverpool, UK
Lung cancer screening in the UK ( Prof John Field - University of Liverpool, Liverpool, UK )
6 Oct 2016
Screening, surgical cure and new developments: Future smart surgical approaches...
Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan...
Screening, surgical cure and new developments: Future smart surgical approaches for brain mets ( Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy )
6 Oct 2016
ALK mutations in paediatric tumours
Dr Suzanne Turner - Cambridge University, Cambridge, UK
ALK mutations in paediatric tumours ( Dr Suzanne Turner - Cambridge University, Cambridge, UK )
5 Oct 2016
NSCLC biology and new therapies: Reversing resistance
Prof Michael Seckl - Imperial College London, London, UK
NSCLC biology and new therapies: Reversing resistance ( Prof Michael Seckl - Imperial College London, London, UK )
5 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation